I-Corps: Development and Commercial Feasibility of a Microfluidic Drug Discovery Kit

I-Corps：微流控药物发现试剂盒的开发和商业可行性

• 批准号: 1355920
• 负责人: Siva Vanapalli
• 金额: $ 5万
• 依托单位: Texas Tech University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-10-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1355920&HistoricalAwards=false
• 关键词: Corps; Development; Commercial; Feasibility; Microfluidic

The proposed innovation uses microfluidic technology to rapidly generate fluid mixtures of drugs with fine increments in their proportions to assist with combination drug development. Although automated pipetting systems and well plates have been the workhorse for primary drug screening where thousands of individual compounds are tested, few, if any, are flexible for screening combination drugs because of the complexity involved in scanning a large number of drug-and-dose combinations. This technology involves injecting plugs of drug solutions into a uniquely designed microfluidic device that allows autonomous mixing and dilution. This approach allows mixing drugs in very fine increments with significantly less consumption of drug samples and reagents. Development of a microfluidic drop technology for combination drug discovery may accelerate the process of drug screening and discovery of new or combination drugs. It would help to reduce the drug development time cycle and cost as it facilitates fluid mixtures of drugs in very small increments. Outside of the pharmaceutical industry, this technology could also play a role in combinational mixing of consumer products and biomaterials.

拟议的创新使用微流体技术来快速生成药物的流体混合物，并以其比例的良好增量来帮助结合药物开发。尽管自动化的移液系统和井板一直是用于原发性药物筛查的主力，因为在扫描大量药物和剂量的情况下，由于筛查组合药物的复杂性，数以千计的单个化合物经过测试，很少（如果有的话）可以灵活地用于筛查组合药物组合。该技术涉及将药物溶液的插头注入独特设计的微流体设备，该设备允许自主混合和稀释。这种方法允许将药物以非常细的增量与药物样品和试剂的消耗大大减少。开发用于组合药物发现的微流体滴技术可能会加速药物筛查和发现新的或组合药物的过程。这将有助于减少药物开发时间周期和成本，因为它促进药物的流体混合物以很小的增量。在制药行业之外，这项技术还可以在结合消费产品和生物材料的结合中发挥作用。